European Heart Journal vs Journal of Clinical Oncology: Which Journal Should You Choose?

EHJ asks whether the paper matters to cardiologists. JCO asks whether the paper matters to oncologists.

That's the whole decision in one sentence.

If the manuscript depends on ESC relevance, cardiovascular surveillance, imaging, heart-failure logic, or cardiac outcomes interpretation, EHJ usually becomes the better home. If the manuscript depends on treatment strategy, oncology outcomes, survivorship implications, or broad cancer-care interpretation, JCO usually becomes the better home.

EHJ wins when the cardio-oncology manuscript is fundamentally a cardiovascular paper.

That usually means:

• cardiotoxicity surveillance and management
• cardiovascular risk after cancer therapy
• imaging or biomarker work that cardiologists must act on
• cardio-oncology registry or observational studies with clear cardiovascular practice implications

The EHJ source set repeatedly emphasizes broad cardiology consequence, ESC-facing context, and field-wide importance.

JCO wins when the manuscript is fundamentally an oncology paper.

That includes:

• clinical oncology studies where cardiac endpoints matter but are still part of a broader oncology question
• survivorship work where the central decisions still belong to oncologists
• treatment interpretation or outcomes papers whose main audience is cancer clinicians
• broad oncology analyses where cardiovascular risk is important, but not the primary readership driver

The JCO sources are clear that the journal wants broad oncology consequence and a complete evidence package for oncology readers.

submission's editorial guidance pushes authors to connect findings to ESC guidelines, European cardiovascular practice, registries, and broad cardiology consequence. That's a signal that the paper belongs there only if the cardiovascular angle is the real headline.

JCO fit and submission's editorial guidance repeatedly emphasize broad oncology readership, treatment interpretation, and high-consequence clinical or translational work. That makes it a much better home for oncology-led cardio-oncology studies than many cardiology journals.

Cardiology language, cardiovascular risk logic, and imaging or outcome nuance aren't weaknesses there. They're expected.

Oncology treatment logic, patient management, and cancer-outcome reasoning are expected there, even when cardiovascular toxicity is a major component.

• the paper is fundamentally cardiovascular
• cardiologists are the main audience
• cardiovascular outcomes, surveillance, or ESC-facing relevance are central
• the manuscript becomes stronger when written for cardiology readers

That's the EHJ lane.

• the paper is fundamentally oncology-led
• oncologists are the main audience
• treatment strategy, survivorship, or broad oncology consequence is central
• the manuscript becomes stronger when written for oncology readers

That's the JCO lane.

This isn't a simple prestige cascade.

A paper rejected by EHJ does not automatically become a JCO paper, and vice versa.

The cascade only works when the first journal saw the manuscript as belonging more naturally to the other specialty.

That can happen when:

• the paper sits at the cardio-oncology boundary
• the methods are strong
• the question is important to both fields
• the first journal judged that the primary readership was actually the other specialty

It doesn't work when the study is simply too narrow or too weak for either field-leading journal.

If the cardiovascular consequence feels secondary to the cancer story, EHJ gets harder quickly.

If the main practical readers are cardiologists and the oncology story is mostly context, JCO gets harder quickly.

The journal still wants broad cardiology importance, not only a decent cardio-oncology analysis.

Interesting but narrow results often look better in a more focused oncology title.

These are usually cleaner EHJ papers when the goal is to change cardiovascular practice.

These are often cleaner JCO papers when the main decisions still belong to oncologists.

The key question is which field's readers need the evidence first. That usually tells you the right target.

These can go either way, but only if the manuscript is honest about whether the intervention or implication is oncology-led or cardiology-led.

A strong EHJ first page makes the cardiovascular consequence obvious immediately. The reader should understand why cardiologists need this paper now.

A strong JCO first page makes the oncology consequence obvious immediately. The reader should understand why oncologists need this paper now.

If both first pages sound equally necessary, the manuscript may still be undecided about its true audience.

Ask which sentence fits the manuscript better:

• "this changes what cardiologists should do or think" points toward European Heart Journal
• "this changes what oncologists should do or think" points toward Journal of Clinical Oncology

That sentence is often the most honest submission test.

At the cardio-oncology boundary, the wrong readership can make a very good paper feel strangely secondary. A study that's perfect for cardiologists can look too supportive for oncologists. A study that's perfect for oncologists can look only indirectly actionable for cardiologists.

That's why audience clarity matters more here than prestige reflexes.

Send to European Heart Journal first if:

1. the paper is fundamentally cardiovascular
2. cardiologists are the readers who most need it
3. ESC-facing relevance or cardiovascular management is central
4. the paper gets stronger when written for cardiology

Send to Journal of Clinical Oncology first if:

1. the paper is fundamentally oncology-led
2. oncologists are the readers who most need it
3. treatment strategy or oncology management is central
4. the paper gets stronger when written for oncology

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.

Submit to European Heart Journal first if:

• The manuscript is fundamentally cardiovascular: cardiotoxicity, cardiovascular outcomes after cancer therapy, or cardiac imaging work that cardiologists must act on
• ESC guidelines, European cardiovascular practice, or cardiac risk management are central to the paper's significance
• Cardiologists are the primary audience who need the result

Think twice about EHJ if:

• The cardiovascular findings are secondary to the oncology treatment story; EHJ will see the misframe quickly and the paper will not survive triage
• The study's primary endpoint is oncological and the cardiac outcomes are safety data; that paper belongs in an oncology journal
• You are submitting to EHJ for the impact factor rather than because cardiology is the correct readership; field mismatch is a fast desk rejection at EHJ

Submit to JCO first if:

• The paper is fundamentally about clinical oncology: treatment, outcomes, survivorship, or evidence interpretation for oncologists
• The primary consequence is what oncologists do with the result, even if cardiovascular endpoints are important
• The manuscript has the broad clinical-oncology consequence that ASCO-centered readers expect

Think twice about JCO if:

• The paper is primarily about cardiovascular management; JCO will redirect that to a cardiology or cardio-oncology specialty journal
• The oncology evidence is early-phase without a clear practice-changing argument; JCO's editorial bar for clinical consequence is high
• The study is regional or limited in generalizability without broader clinical-oncology relevance

In our pre-submission review work with manuscripts targeting both European Heart Journal and Journal of Clinical Oncology, three patterns generate the most consistent mismatch decisions among the papers we analyze.

Cardio-oncology papers submitted to EHJ where the lead is oncological. The most common mismatch we see is a well-designed survivorship or cardiac-toxicity study where the primary endpoints and clinical frame are oncological, submitted to EHJ because cardiology is involved. EHJ editors identify these papers quickly. The journal wants papers where cardiologists are the primary clinical actors. When the main consequence is oncologist behavior, EHJ declines and directs authors toward oncology journals.

JCO submissions without clear practice-changing clinical evidence. JCO is one of the most selective clinical-oncology journals in the world. We see papers with strong observational data or interesting exploratory findings submitted to JCO with the expectation that clinical relevance of the topic will compensate for limited causal evidence. JCO's triage focuses on whether the paper changes what oncologists do. Papers that describe associations without actionable clinical conclusions face a high desk-rejection rate regardless of topic importance.

Papers straddling both fields without committing to either audience. Some cardio-oncology papers are genuinely undecided: the endpoints are mixed, the clinical implications are relevant to both cardiologists and oncologists, and the paper has not decided who it is actually written for. We find these papers fail triage at both journals because neither editorial team can identify who must read this paper to change their practice. Resolving that audience decision before submission is the single most important step in the journal selection process for cardio-oncology work.

SciRev author-reported data confirms that JCO's time to first decision is typically around 4 to 6 weeks. A EHJ vs JCO positioning and cardiology-oncology scope check can identify whether your manuscript is correctly positioned for the journal you're targeting before you submit.

• European Heart Journal submission guide
• Journal of Clinical Oncology submission guide
• How to avoid desk rejection at Journal of Clinical Oncology
• European Heart Journal - Author Guidelines
• JCO - Author Guidelines
• Clarivate Journal Citation Reports (JCR 2024)